留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

神经病理性疼痛的药物治疗进展

赵佳丽 陈秋红 李红娜 曾莉莉 叶永贤 费燕

赵佳丽, 陈秋红, 李红娜, 曾莉莉, 叶永贤, 费燕. 神经病理性疼痛的药物治疗进展[J]. 药学实践与服务, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
引用本文: 赵佳丽, 陈秋红, 李红娜, 曾莉莉, 叶永贤, 费燕. 神经病理性疼痛的药物治疗进展[J]. 药学实践与服务, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
ZHAO Jiali, CHEN Qiuhong, LI Hongna, ZENG Lili, YE Yongxian, FEI Yan. Progress on drug therapy of neuropathic pain[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
Citation: ZHAO Jiali, CHEN Qiuhong, LI Hongna, ZENG Lili, YE Yongxian, FEI Yan. Progress on drug therapy of neuropathic pain[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006

神经病理性疼痛的药物治疗进展

doi: 10.3969/j.issn.1006-0111.2016.04.006
基金项目: 解放军第一七五医院青年苗圃基金课题(15Y008)

Progress on drug therapy of neuropathic pain

  • 摘要: 神经病理性疼痛(NPP)是由一系列感染和神经损伤事件引起的慢性疼痛,其发病率高、病因复杂,严重影响患者的生活质量。尽管临床试验逐渐增多,但NPP的治疗仍存在不足。合理使用不同作用机制和持续时间的药物,是当前治疗NPP的研究热点。针对近年来NPP的药物治疗进展做一总结,为该病的治疗提供依据。
  • [1] Attal N, Bouhassira D. Neuropathic pain:experimental advances and clinical applications[J]. Rev Neurol, 2004, 160(2):199-203.
    [2] Lema MJ, Foley KM, Hausheer FH. Types and epidemiology of cancer-related neuropathic pain:the intersection of cancer pain and neuropathic pain[J]. Oncologist, 2010, 15(Suppl2):3-8.
    [3] Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain:involvement of inflammatory immune cells, immune-like glial cells and cytokines[J]. J Neuroimmunol, 2010, 229(1-2):26-50.
    [4] Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes:mechanisms of action and place in therapy[J]. Drugs, 2000, 60(5):1029-1052.
    [5] Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain[J]. Curr Pain Headache Rep, 2009, 13(3):185-190.
    [6] Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics:a review[J]. J Clin Pharmacol, 2012, 52(1):6-17.
    [7] Watson CP, Chipman M, Reed K, et al. Amitriptyline versus maprotiline, in postherpetic neuralgia:a randomized, double-blind, crossover trial[J]. Pain, 1992, 48(1):29-36.
    [8] Jefferies K. Treatment of neuropathic pain[J]. Semin Neurol, 2010, 30(4):425-432.
    [9] Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain:2010 revision[J]. Eur J Neurol, 2010, 17(9):1113-1188.
    [10] Skljarevski V, Desaiah D, Zhang Q, et al. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain[J]. Diabetes Metab Res Rev, 2009, 25(7):623-631.
    [11] Sultan A, Gaskell H, Derry S, et al. Duloxetine for painful diabetic neuropathy and fibromyalgia pain:systematic review of randomised trials[J]. BMC Neurol, 2008, 8:29.
    [12] Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain:consensus statement and guidelines from the Canadian Pain Society[J]. Pain Res Manag, 2007, 12(1):13-21.
    [13] Dooley DJ, Taylor CP, Donevan S, et al. Ca2+ channel α-2-δ ligands:novel modulators of neurotransmission[J]. Trends Pharmacol Sci, 2007, 28(2):75-82.
    [14] Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain:a randomized controlled trial from the Gabapentin Cancer Pain Study Group[J]. J Clin Oncol, 2004, 22(14):2909-2917.
    [15] Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuopathic pain evaluated in a 12-week, randomized, double-blind, multicenter, placebo-controlled trial of flexible-and fixed-dose regimens[J]. Pain, 2005, 115(3):254-263.
    [16] Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain:A double-blind, randomized controlled crossover trial[J]. Lancet, 2009, 374(9697):1252-1261.
    [17] Griggs RB, Bardo MT, Taylor BK. Gabapentin alleviates affective pain after traumatic nerve injury[J]. Neuroreport, 2015, 26(9):522-527.
    [18] Câmara CC, Araújo CV, de Sousa KKO, et al. Gabapentin attenuates neuropathic pain and improves nerve myelination after chronic sciatic constriction in rats[J]. Neurosci Lett, 2015, 607:52-58.
    [19] Baillie JK, Power I. Morphine, gabapentin, or their combination for neuropathic pain[J]. N Engl J Med, 2005, 352(25):2650-2651.
    [20] García de Paredes ML, del Moral González F, Martínez del Prado P, et al. First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients results of oncology study[J]. Ann Oncol, 2011, 22(4):924-930.
    [21] Sindrup SH, Andersen G, Madsen C, et al. Tramadol relieves pain and allodynia in polyneuropathy:a randomized, double-blind, controlled, trial. Pain, 1999, 83(1):85-90.
    [22] Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain:an overview and literature update[J]. Mayo Clin Proc,2010,85(3):S3-S14.
    [23] Suzuki R, Matthews EA, Dickenson AH. Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy[J]. Pain, 2001, 91(1-2):101-109.
    [24] Vadivelu N, Hines RL. Buprenorphine:a unique opioid with broad clinical applications[J]. J Opioid Manag, 2007, 3(1):49-58.
    [25] Vadivelu N, Hines RL. Management of chronic pain in the elderly:focus on transdermal buprenorphine[J]. Clin Interv Aging, 2008, 3(3):421-430.
    [26] Johnson RE, Fudala PJ, Payne R. Buprenorphine:considerations for pain management[J]. J Pain Symptom Manage, 2005, 29(3):297-326.
    [27] Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain[J]. J Pain, 2009, 10(2):113-130.
    [28] 神经病理性疼痛诊疗专家组. 神经病理性疼痛诊疗专家共识[J]. 中国疼痛医学杂志,2013,19(12):705-710.
    [29] Müller-Schwefe G, Jaksch W, Morlion B, et al. Make a change:optimizing communication and pain management decisions[J]. Curr Med Res Opin, 2011, 27(2):481-488.
  • [1] 王宏播, 卞康晴, 郭灵怡, 代宇, 俞媛.  外泌体用于疾病诊疗和药物递送的研究进展 . 药学实践与服务, 2023, 41(5): 265-272, 320. doi: 10.12206/j.issn.2097-2024.202207022
    [2] 龚晓斌, 刘诗怡, 夏天一, 位华, 陈万生.  阿帕替尼在恶性肿瘤治疗中的临床应用与研究进展 . 药学实践与服务, 2018, 36(2): 103-107,130. doi: 10.3969/j.issn.1006-0111.2018.02.002
    [3] 卞莹莹, 王洁, 李安, 开国银, 陆一鸣.  炎症性肠病的药物治疗现状 . 药学实践与服务, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002
    [4] 雷永芳, 凌青.  良性前列腺增生症的药物治疗及个体化用药 . 药学实践与服务, 2017, 35(5): 447-448,456. doi: 10.3969/j.issn.1006-0111.2017.05.015
    [5] 马宗强, 安洪亮.  门诊口服抗高血压药物的调查分析 . 药学实践与服务, 2016, 34(2): 188-190,192. doi: 10.3969/j.issn.1006-0111.2016.02.024
    [6] 陈开宇, 江丽萍, 陈盛新.  慢性阻塞性肺疾病的药物治疗进展 . 药学实践与服务, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
    [7] 陈婷, 鲁莹.  载抗肿瘤药物纳米靶向给药系统的研究进展 . 药学实践与服务, 2011, 29(3): 176-178,196.
    [8] 黄景彬, 钟延强.  乳腺癌靶向治疗的新策略 . 药学实践与服务, 2011, 29(5): 324-327.
    [9] 傅翔, 栾智鹏, 陈盛新.  用药安全 . 药学实践与服务, 2009, 27(3): 236-240.
    [10] 丁晴雪, 栾智鹏, 陈盛新.  如何制定、实施和监测药物治疗方案 . 药学实践与服务, 2009, 27(4): 317-320.
    [11] 冯惠坚, 栾智鹏, 陈盛新.  医院药师如何开展循证药物治疗 . 药学实践与服务, 2009, 27(6): 476-480.
    [12] 蒋宁君, 毕新岭, 顾军, 宋书伟.  银屑病的中西医药物治疗近况 . 药学实践与服务, 2008, (6): 412-413,449.
    [13] 薛龙, 孙爱军.  恶性肿瘤靶向治疗方法的进展及应用 . 药学实践与服务, 2008, (2): 81-83.
    [14] 赵民生, 曹秀虹.  利尿剂在治疗心血管疾病时的不良反应及处理 . 药学实践与服务, 2006, (6): 353-354.
    [15] 徐国华, 雷招宝.  治疗慢性丙型肝炎新药——聚乙二醇干扰素α-2b . 药学实践与服务, 2005, (6): 350-353.
    [16] 唐斌, 何佩珍, 徐帆, 尚北城.  黄连素的联合用药 . 药学实践与服务, 2005, (5): 278-281.
    [17] 郭随章.  糖尿病周围神经病变的药物治疗 . 药学实践与服务, 2003, (3): 131-133.
    [18] 田维荣, 戴飞龙, 晏马成.  糖尿病的药物治疗 . 药学实践与服务, 2002, (3): 137-140.
    [19] 张丽梅, 王卓, 徐慧欣, 杨樟卫, 胡晋红.  复发性口腔溃疡的药物治疗 . 药学实践与服务, 2001, (3): 140-142.
    [20] 张生大.  双嘧达莫与其它药物合用的新用途 . 药学实践与服务, 2001, (1): 13-13.
  • 加载中
计量
  • 文章访问数:  3121
  • HTML全文浏览量:  343
  • PDF下载量:  851
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-12-28
  • 修回日期:  2016-01-08

神经病理性疼痛的药物治疗进展

doi: 10.3969/j.issn.1006-0111.2016.04.006
    基金项目:  解放军第一七五医院青年苗圃基金课题(15Y008)

摘要: 神经病理性疼痛(NPP)是由一系列感染和神经损伤事件引起的慢性疼痛,其发病率高、病因复杂,严重影响患者的生活质量。尽管临床试验逐渐增多,但NPP的治疗仍存在不足。合理使用不同作用机制和持续时间的药物,是当前治疗NPP的研究热点。针对近年来NPP的药物治疗进展做一总结,为该病的治疗提供依据。

English Abstract

赵佳丽, 陈秋红, 李红娜, 曾莉莉, 叶永贤, 费燕. 神经病理性疼痛的药物治疗进展[J]. 药学实践与服务, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
引用本文: 赵佳丽, 陈秋红, 李红娜, 曾莉莉, 叶永贤, 费燕. 神经病理性疼痛的药物治疗进展[J]. 药学实践与服务, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
ZHAO Jiali, CHEN Qiuhong, LI Hongna, ZENG Lili, YE Yongxian, FEI Yan. Progress on drug therapy of neuropathic pain[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
Citation: ZHAO Jiali, CHEN Qiuhong, LI Hongna, ZENG Lili, YE Yongxian, FEI Yan. Progress on drug therapy of neuropathic pain[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
参考文献 (29)

目录

    /

    返回文章
    返回